HUP0500851A3 - Process for the preparation of rosuvastatin - Google Patents

Process for the preparation of rosuvastatin

Info

Publication number
HUP0500851A3
HUP0500851A3 HU0500851A HUP0500851A HUP0500851A3 HU P0500851 A3 HUP0500851 A3 HU P0500851A3 HU 0500851 A HU0500851 A HU 0500851A HU P0500851 A HUP0500851 A HU P0500851A HU P0500851 A3 HUP0500851 A3 HU P0500851A3
Authority
HU
Hungary
Prior art keywords
rosuvastatin
preparation
Prior art date
Application number
HU0500851A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of HUP0500851A2 publication Critical patent/HUP0500851A2/hu
Publication of HUP0500851A3 publication Critical patent/HUP0500851A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0500851A 2002-12-10 2002-12-10 Process for the preparation of rosuvastatin HUP0500851A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005213 WO2004052867A1 (en) 2002-12-10 2002-12-10 Process for the preparation of rosuvastatin

Publications (2)

Publication Number Publication Date
HUP0500851A2 HUP0500851A2 (en) 2007-08-28
HUP0500851A3 true HUP0500851A3 (en) 2008-02-28

Family

ID=32500442

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500851A HUP0500851A3 (en) 2002-12-10 2002-12-10 Process for the preparation of rosuvastatin

Country Status (11)

Country Link
US (1) US7566782B2 (OSRAM)
EP (1) EP1578733B1 (OSRAM)
CN (1) CN1742000A (OSRAM)
AT (1) ATE501126T1 (OSRAM)
AU (1) AU2002348881A1 (OSRAM)
CA (1) CA2509619A1 (OSRAM)
DE (1) DE60239428D1 (OSRAM)
DK (1) DK1578733T3 (OSRAM)
HU (1) HUP0500851A3 (OSRAM)
SI (1) SI1578733T1 (OSRAM)
WO (1) WO2004052867A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000322A (es) 2001-07-13 2005-09-08 Astrazeneca Uk Ltd Preparacion de compuestos de aminopirimidina.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
EP1673351A1 (en) 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2591439C (en) 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20090124803A1 (en) * 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
US20080161560A1 (en) * 2005-04-04 2008-07-03 Pandurang Balwant Deshpande Process for Preparation of Calcium Salt of Rosuvastatin
CN1307187C (zh) * 2005-05-16 2007-03-28 浙江海正药业股份有限公司 瑞舒伐他汀及其中间体的制备方法
EP1893585A1 (en) * 2005-06-01 2008-03-05 Fermion Oy Process for the preparation of n-[4-(4-fluorophenyl)-5-formyl-6-isopropyl-pyrimidin-2-yl]-n-methylmethanesulfonamide
CN102807530B (zh) 2005-06-24 2015-08-05 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
CZ299215B6 (cs) * 2005-06-29 2008-05-21 Zentiva, A. S. Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny
MX2007004427A (es) 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
MX2007006647A (es) * 2005-10-04 2007-07-25 Teva Pharma Preparacion de rosuvastatina.
WO2008053334A2 (en) 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
WO2008072078A1 (en) * 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
EP2125754B1 (en) 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
KR101157314B1 (ko) 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
EP2336116A1 (en) 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
KR101292238B1 (ko) 2010-07-01 2013-07-31 주식회사유한양행 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 그의 중간체의 제조방법
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
CN102358747B (zh) * 2011-08-30 2012-09-19 浙江宏元药业有限公司 瑞舒伐他汀钙中间体及制备瑞舒伐他汀钙中间体和瑞舒伐他汀钙的方法
WO2015074328A1 (zh) * 2013-11-25 2015-05-28 复旦大学 一种瑞舒伐他汀钠的制备方法
CN103601687A (zh) * 2013-11-25 2014-02-26 复旦大学 一种瑞舒伐他汀钠的制备方法
CN104230990B (zh) * 2014-08-15 2016-05-11 新发药业有限公司 2-((4r,6s)-6-三苯基膦烯甲叉基-2,2-二取代基-1,3-二氧六环-4-基)乙酸酯及其制备方法与应用
CN104630297B (zh) * 2014-12-10 2018-07-06 江南大学 一种酶法非水相催化合成(r)-3-tbdmso戊二酸甲单酯及其衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
EP1578733A1 (en) 2005-09-28
CN1742000A (zh) 2006-03-01
DK1578733T3 (da) 2011-06-14
US20060149065A1 (en) 2006-07-06
WO2004052867A1 (en) 2004-06-24
AU2002348881A1 (en) 2004-06-30
DE60239428D1 (OSRAM) 2011-04-21
HUP0500851A2 (en) 2007-08-28
US7566782B2 (en) 2009-07-28
SI1578733T1 (sl) 2011-07-29
ATE501126T1 (de) 2011-03-15
CA2509619A1 (en) 2004-06-24
EP1578733B1 (en) 2011-03-09

Similar Documents

Publication Publication Date Title
HUP0500851A3 (en) Process for the preparation of rosuvastatin
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
TWI350831B (en) Process for the preparation of ring compounds
HRP20050328A2 (en) Process for the preparation of (s,s)-cis-2-benzhyd
PT1578731E (pt) Processo para a preparação de compostos pirimidina
IL143106A (en) Process for the preparation of diphenylmethylthioacetamide
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
TWI347945B (en) Process for the preparation of thiazolopyrimidines
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
PL373627A1 (en) Process for the preparation of melamine
EG23973A (en) Process for the preparation of urea ganules
PL371583A1 (en) Process for the preparation of 7alpha-methylsteroids
AU2003225426A1 (en) Process for the preparation of urea
AU2003278420A8 (en) Process for the preparation of ganciclovir
SG111997A1 (en) Improved process for the preparation of polyalkylphenoxyaminoalkanes
AU2002359034A1 (en) Process for the preparation of simvastatin
HUP0303025A3 (en) Process for the preparation of arylethanoldiamines
IL164788A0 (en) Process for the preparation of 3-isochromanone
IL161897A0 (en) Process for the preparation of cephalexin
ZA200603113B (en) Process for the preparation of risperidone
PL368905A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
ZA200509495B (en) Process for the preparation of nicotinaldehydes
PL374911A1 (en) Process for the preparation of zaleplon

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees